The pipeline in headache therapy

CNS Drugs

Volumn 27, Issue 9, 2013, Pages 717-729

  Vollbracht, Sarah ^a   Rapoport, Alan M ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALSUMA; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CIS CAPSAICIN; DICLOFENAC POTASSIUM; DIHYDROERGOTAMINE MESILATE; IBUDILAST; OPTINOSE; SEROTONIN 1 AGONIST; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; GLIA CELL; HEADACHE; HUMAN; NERVE STIMULATION; PRIORITY JOURNAL; REVIEW; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; HEADACHE; HUMANS; MIGRAINE DISORDERS; OREXIN RECEPTORS; SEROTONIN RECEPTOR AGONISTS;

EID: 84883259160     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0090-x     Document Type: Review

References (98)

1. Robbins MS, Lipton RB. The epidemiology of primary headache disorders. Semin Neurol. 2010;30(2):107-19.
2. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668-75.
3. Cambia (™) [prescribing information]. Nautilus Neurosciences, Inc.: Bedminster; 2010.
4. Diener H-C, Montagna P, Gàcs G, Lyczak P, Schumann G, Zoller B, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26(5):537-47.
5. Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010;30(11):1336-45.
6. Brandes JL, Cady RK, Freitag FG, Smith TR, Chandler P, Fox AW, et al. Needle-free subcutaneous sumatriptan (Sumavel(™) DosePro(™)): bioequivalence and ease of use. Headache. 2009;48:355-67.
7. SUMAVEL® DosePro® [prescribing information]. Zogenix: San Diego; 2011.
8. Rothrock JF, Cady RK, Aurora SK, Brandes JL, Meyers JA, Fox AW, et al. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-related functionality, satisfaction, and confidence. Curr Med Res Opin. 2011;27(11):2185-91.
9. Cady RK, Aurora SK, Brandes JL, Rothrock JF, Myers JA, Fox AW, et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache. 2011;51:1202-11.
10. Patel SR, Zhong H, Sharma A, Kalia YN. In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharmaceut Biopharmaceut. 2007;66:296-301.
11. Vikelis M, Mitsikostas D, Rapoport AM. Sumatriptan transdermal iontophoretic patch (NP101-Zelrix(™)): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatr Dis Treat. 2012;8:429-34.
12. Zecuity(™) [prescribing information]. Nupathe, Inc.: Conshohocken; 2013.
13. Siegel SJ, O'Neill CO, Dube LM, Kaldeway P, Morris R, Jackson D, et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res. 2007;24(10):1919-26.
14. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. Zelrix(™): a novel transdermal formulation of sumatriptan. Headache. 2009;49:817-25.
15. Goldstein J, Smith TR, Pugach N, Griesser M, Sebree T, Pierce M. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012;52:1402-10.
16. Smith TR, Goldstein J, Singer R, Pugach N, Silberstein S, Pierce MW. Twelve-month tolerability and efficacy study of np101, the sumatriptan iontophoretic transdermal system. Headache. 2012;52:612-24.
17. Alsuma(™) [prescribing information]. Pfizer Inc.: New York; 2012.
18. Landy SH, Tepper SJ, Wein T, Schweizer E, Ramos E. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. Headache. 2013;53(1):118-25.
19. Silberstein S. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother. 2012;13(13):1961-8.
20. Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo(™)) inhaler. Headache. 2008;48:355-67.
21. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009;49:826-37.
22. Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51:507-17.
23. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19-26.
24. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55(1):27-36.
25. Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT, et al. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraine with and without allodynia. Headache. 2012;52:37-47.
26. Luthringer R, Djupesland PG, Sheldrake CD, Flint A, Boeijinga P, Danjou P, et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol. 2009;61(9):1219-28.
27. Djupesland PG, Docekal P, Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia. 2010;30(8):933-42.
28. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48-56.
29. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999;76(2-3):176-83.
30. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683-96.
31. Edvinsson L, Gulbenkian S, Barrosco CP, Cunha e Sá M, Polack JM, Mortensen A, et al. Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides. 1998;19(7):1213-25.
32. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-7.
33. Gallai V, Sarchielli P, Floridi A, Franceschini M, Cadini M, Glioti G, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15:384-90.
34. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193-6.
35. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin-gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995;60(2):119-23.
36. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;142(7):1171-81.
37. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules, and therapeutics. Trends Mol Med. 2007;13(1):39-44.
38. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104-10.
39. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304-12.
40. Hewitt DJ, Martin V, Lipton RB, Brandes J, Ceesay P, Gottwald R, et al. Randomized controlled study of telcagepant plus ibuprofen or acetominophen in migraine. Headache. 2011;51:533-43.
41. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115-23.
42. Connor KM, Shapiro RE, Diener HC, Lucus S, Kost J, Fan X, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73(12):970-7.
43. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31(6):712-22.
44. Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache. 2012;52(2):224-35.
45. van der Schueren BJ, Blanchard R, Murphy MG, Palcza J, De Lepeleire I, Van Hecken A, et al. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2010;71(5):708-17.
46. Ho AP, Dahlof CG, Silberstein SD, Saper JR, Ashina M, Kost JT, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30(12):1443-57.
47. Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011;51(1):73-84.
48. Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache. 2011;51(1):64-72.
49. Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol. 2012;14(1):50-9.
50. Han TH, Blanchard RL, Palcza J, McCrea JB, Laethem T, Willson K, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol. 2010;50(12):1367-76.
51. Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine: results from a phase II study. Cephalalgia. 2011;31(5):573-84.
52. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine: current understanding and state of development. Headache. 2013 (in press).
53. Neeb L, Meents J, Reuter U. 5-HT-1F receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics. 2010;7:176-82.
54. Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauass M. Acute treatment of migraine with the selective 5-HT-1F receptor agonist lasmitidan - a randomised proof-of-concept trial. Cephalalgia. 2010;30:1170-8.
55. Fakkila M, Diener HC, Geraud G, Laniz JM, Schoenen J, Pilgrim AJ. Lasmitidan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine. J Headache Pain. 2010;11(Suppl 1):S43.
56. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia. 1996;16:310-6.
57. Rapoport AM. The therapeutic future in headache. Neurol Sci. 2012;22(Suppl 1):S119-25.
58. Saper JR, Klapper J, Mathew NT, Rapoport A, Phillips SB, Bernstein JE. Intranasal civamide for the treatment of episodic cluster headache. Arch Neurol. 2002;59:990-4.
59. Civamide nasal solution for cluster headache (ECH). NCT01341548. http://clinicaltrials.gov/ct2/show/NCT01341548. Accessed 26 Feb 2013.
60. Diamond S, Freitag F, Phillips SB, Bernstein JE, Saper JR. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia. 2000;20:597-602.
61. Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypcretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain. 2004;109:367-78.
62. Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci. 2006;24:2825-33.
63. Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, et al. Pharmacololgical characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology. 2012;62:978-87.
64. A study of the safety and efficacy of MK-6096 for migraine prophylaxis in participants with episodic migraine (MK-6096-020). NCT01513291. http://clinicaltrials.gov/ct2/show/NCT01513291. Accessed 26 Feb 2013.
65. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169:683-96.
66. Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res Brain Res Rev. 2005;48(3):457-76.
67. Garrison CJ, Dougherty PM, Carlton SM. GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801. Exp Neurol. 1994;129:237-43.
68. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24(8):450-5.
69. Wieseler-Frank J, Maier SF, Watkins LR. Glial activation and pathological pain. Neurochem Int. 2004;45(2-3):389-95.
70. Takeda M, Takahashi M, Matsumoto S. Contribution of the activation of satellite glia in sensory ganglia to pathological pain. Neurosci Biobehav Rev. 2009;33(6):784-92.
71. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008-23.
72. Capuano A, DeCorato A, Lisi L, Tringali G, Navarra P, Dello Russo C. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain. 2009;5:43-55.
73. Kruuse C, Thomsen LL, Jacobsen TB, Olesen J. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab. 2002;22(9):1124-31.
74. Ledeboer A, Tongyao L, Ahumilla JA, Mahoney JH, Vijay S, Gross MI, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glio Biol. 2006;2:279-291.
75. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs. 2007;16(7):935-50.
76. Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS. Occipital nerve stimulation for chronic headache - long-term safety and efficacy. Cephalalgia. 2007;27(2):153-7.
77. Matharu MS, Bartsch T, Ward N, Frackowiak RSJ, Weiner R, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127(Pt 1):220-30.
78. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011;31(3):271-85.
79. Reed KL, Black SB, Banta CJ II, Will KR. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia. 2010;30(3):260-71.
80. Schytz HW, Barlose M, Guo S, Selb J, Caparso A, Jensen R, et al. Experimental activation of the sphenopalatine ganglion provokes cluster-like attacks in humans. Cephalalgia. 2013, 1-11 (Epub ahead of print).
81. Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, Ansarinia M. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache. 2009;49(7):983-9.
82. Schoenen J, Jensen RH, Lanteri-Minet M, Lainez MJ, Gaul C, Goodman AM, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia. 2013;6:1-15 (Epub ahead of print).
83. Sadler RM, Purdy RA, Rahey S. Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia. 2002;22(6):482-4.
84. Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia. 2005;25(2):82-6.
85. Hord ED, Evans MS, Mueed S, Adamolekun B, Naritoku DK. The effect of vagus nerve stimulation on migraines. J Pain. 2003;4(9):530-4.
86. Lenaerts ME, Oommen KJ, Couch JR, Skaggs V. Can vagus nerve stimulation help migraine? Cephalalgia. 2008;28(4):392-5.
87. Cecchini AP, Mea E, Tullo V, Curone M, Franzoni A, Broggi G, et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression preliminary data. Neurol Sci. 2009;30(Suppl 1):S101-4.
88. Oshinsky ML, Murphy AL, Cooper ME, Simon BJ. Trigeminal pain is suppressed by non-invasive vagal nerve stimulation in a rat headache model. J Headache Pain. 2013;1(Suppl 1):P80.
89. Goadsby P. Non-invasive vagus nerve stimulation (nVNS) for acute treatment of migraine: an open-label pilot study. American Academy of Neurology's 65th AAN annual meeting, San Diego.
90. Nesbitt AD, Marin JCA, Tomkins E, Ruttledge MH, Goadsby PJ. Non-invasive vagus nerve stimulation for the treatment of cluster headache: a case series. J Headache Pain. 2013;1(Suppl 1):P231.
91. Gerardy PY, Fabry D, Fumal A, Schoenen J. A pilot study on supra-orbital surface electrotherapy in migraine. Cephalalgia. 2009;29:134.
92. Schoenen J, Vandermissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80(8):697-704.
93. Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomized, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373-80.
94. Clarke BM, Upton ARM, Kamath MV, Al-Harbi T, Castellasnos CM. Transcranial magnetic stimulation for migraine: clinical effects. J Headache Pain. 2006;7(5):341-6.
95. Teepker M, Hotzel J, Timmesfeld N, Reis J, Mylius V, Haag A, et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia. 2010;30(2):137-44.
96. Bringhina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O, et al. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci. 2004;227(1):67-71.
97. Misra UK, Kalita J, Bhoi SK. High frequency repetitive transcranial magnetic stimulation (rTMS) is effective in migraine prophylaxis: an open labeled study. Neurol Res. 2012;34(6):547-51.
98. Antal A, Kriener N, Lang N, Boros K, Paulus W. Cathodal transcranial direct current stimulation of the visual cortex in the prophylactic treatment of migraine. Cephalalgia. 2011;31(7):820-8.